Medical Equipment

Pharmacogenomics Market Forecast Through 2030 With Insights On Market Patterns And Developments

April 15, 2026April 15, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Pharmacogenomics Market Expected To Change From 2026 To 2030?

The pharmacogenomics market has experienced significant expansion recently. The market is projected to expand from $9.84 billion in 2025 to $10.85 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.3%. This historical expansion can be attributed to increasing genomic research activities, broader development of targeted therapies, a rise in chronic disease prevalence, advancements in sequencing technologies, and wider access to genetic testing services.

The pharmacogenomics market is projected to experience substantial expansion in the coming years. Its valuation is set to reach $15.98 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.2%. This anticipated growth over the forecast period stems from factors such as heightened investments in precision medicine initiatives, the escalating use of AI-powered genomic analysis, the broadened application of pharmacogenomics within oncology and cardiology, an intensified emphasis on personalized drug development, and ongoing innovations in bioinformatics platforms. Key developments expected during this period encompass a wider embrace of personalized medicine strategies, an increase in genetic testing for drug selection, greater incorporation of pharmacogenomic data into clinical practices, the proliferation of companion diagnostics, and a sharpened focus on precision therapeutics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report

Which Primary Drivers Are Impacting The Pharmacogenomics Market Growth?

The rising incidence of chronic illnesses is anticipated to drive the expansion of the pharmacogenomics market in the future. These conditions are defined as health issues that endure for a prolonged duration, frequently throughout an individual’s life. The surge in chronic diseases stems from the longer average lifespan globally and the prevalent embrace of lifestyle risk factors like inactive routines, unhealthy eating habits, and tobacco use. Pharmacogenomics provides a tailored method for managing chronic illnesses, considering specific genetic differences that influence how drugs affect individuals. As an illustration, in 2025, data from the International Diabetes Federation, a health organization based in Belgium, indicated that in 2024, approximately 589 million adults aged 20-79 had diabetes. This figure is forecasted to climb to 853 million by 2050, with over 4 in 5 diabetic adults living in low and middle income countries. Consequently, the growing prevalence of chronic diseases is fueling the expansion of the pharmacogenomics market.

How Is The Pharmacogenomics Market Segmented Across Different Segment Categories?

The pharmacogenomics market covered in this report is segmented –

1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies

2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications

3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users

Subsegments:

1) By Next Generation Sequencing (NGS): Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing

2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR

3) By Gel Electrophoresis: Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophoresis, Capillary Gel Electrophoresis

4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry), MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight), HRMS (High-Resolution Mass Spectrometry)

5) By Microarray: SNP Microarrays, Expression Microarrays, Comparative Genomic Hybridization (CGH) Arrays

6) By Other Technologies: Sanger Sequencing, CRISPR-Based Technologies, Bioinformatics Tools

Which Trends Are Shaping Growth In The Pharmacogenomics Market?

Leading companies operating within the pharmacogenomics market are increasingly concentrating on artificial intelligence (AI) driven models for managing drug-drug interactions (DDIs) at the genomic level, which in turn enhances medication safety, diminishes adverse reactions, and facilitates highly personalized prescribing. AI-powered pharmacogenetics engines are advanced digital systems that utilize artificial intelligence to analyze an individual’s genetic profile and predict their response to particular medications. For instance, in December 2024, PGxAI, a US-based artificial intelligence (AI) driven pharmacogenetics company, introduced its Sirius model, an AI-powered pharmacogenetics engine designed to personalize drug selection, dosage, and drug-drug interaction management based on an individual’s genome. Sirius encompasses 730 drugs and 40 key pharmacogenes, providing a much broader scope than traditional pharmacogenomic solutions. This model is engineered for use by hospital systems, diagnostic labs, and clinical research organizations, aiding in the reduction of adverse reactions and the improvement of therapeutic outcomes.

Which Organizations Play A Role In The Pharmacogenomics Market Landscape?

Major companies operating in the pharmacogenomics market are Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, PerkinElmer Inc, Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc, Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc, Berry Genomics, BGI, GenomiCare Biotechnology, F Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V, Centro de Genoma e Biologia de Sistemas, Datar Cancer Genetics Limited, MedGenome Labs, 23andMe, Color Genomics, Pathway Genomics, Genomika Diagnósticos

Get The Full Pharmacogenomics Market Report:

https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report

Which Region Leads The Pharmacogenomics Market In Terms Of Market Share?

North America was the largest region in the pharmacogenomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Pharmacogenomics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report

Browse Through More Reports Similar to the Global Pharmacogenomics Market 2026, By The Business Research Company

Pharma 4 0 Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharma-4-0-global-market-report

Consumer Genomics Market Report 2026

https://www.thebusinessresearchcompany.com/report/consumer-genomics-global-market-report

Pharmaceutical Label Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-label-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795